SYRE

Spyre Therapeutics' stock has been impacted by positive clinical trial data, specifically the Phase 2 SKYLINE trial for SPY001, which led to a significant increase in the stock price. The company announced and closed public offerings of common stock, including a $403.0 million offering in April 2026. Spyre announced the completion of recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial and accelerated the expected Week 12 topline readout to Q3 2026. The company reported its Q1 2026 financial results, showing a net loss of $69.0 million, but its pro forma cash position was $1.1768 billion. CEO Cameron Turtle sold 15,000 shares of the company's stock. Spyre Therapeutics has received a consensus "Buy" rating from analysts, with an average price target of $89.08 as of May 2026.